Unknown

Dataset Information

0

Highly efficient editing of the ?-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.


ABSTRACT: Sickle cell disease (SCD) is a monogenic disorder that affects millions worldwide. Allogeneic hematopoietic stem cell transplantation is the only available cure. Here, we demonstrate the use of CRISPR/Cas9 and a short single-stranded oligonucleotide template to correct the sickle mutation in the ?-globin gene in hematopoietic stem and progenitor cells (HSPCs) from peripheral blood or bone marrow of patients with SCD, with 24.5 ± 7.6% efficiency without selection. Erythrocytes derived from gene-edited cells showed a marked reduction of sickle cells, with the level of normal hemoglobin (HbA) increased to 25.3 ± 13.9%. Gene-corrected SCD HSPCs retained the ability to engraft when transplanted into non-obese diabetic (NOD)-SCID-gamma (NSG) mice with detectable levels of gene correction 16-19 weeks post-transplantation. We show that, by using a high-fidelity SpyCas9 that maintained the same level of on-target gene modification, the off-target effects including chromosomal rearrangements were significantly reduced. Taken together, our results demonstrate efficient gene correction of the sickle mutation in both peripheral blood and bone marrow-derived SCD HSPCs, a significant reduction in sickling of red blood cells, engraftment of gene-edited SCD HSPCs in vivo and the importance of reducing off-target effects; all are essential for moving genome editing based SCD treatment into clinical practice.

SUBMITTER: Park SH 

PROVIDER: S-EPMC6735704 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.

Park So Hyun SH   Lee Ciaran M CM   Dever Daniel P DP   Davis Timothy H TH   Camarena Joab J   Srifa Waracharee W   Zhang Yankai Y   Paikari Alireza A   Chang Alicia K AK   Porteus Matthew H MH   Sheehan Vivien A VA   Bao Gang G  

Nucleic acids research 20190901 15


Sickle cell disease (SCD) is a monogenic disorder that affects millions worldwide. Allogeneic hematopoietic stem cell transplantation is the only available cure. Here, we demonstrate the use of CRISPR/Cas9 and a short single-stranded oligonucleotide template to correct the sickle mutation in the β-globin gene in hematopoietic stem and progenitor cells (HSPCs) from peripheral blood or bone marrow of patients with SCD, with 24.5 ± 7.6% efficiency without selection. Erythrocytes derived from gene-e  ...[more]

Similar Datasets

| S-EPMC5087995 | biostudies-literature
| S-EPMC8120141 | biostudies-literature
| S-EPMC6512986 | biostudies-literature
| S-EPMC5500303 | biostudies-literature
| S-EPMC5835144 | biostudies-literature
| S-EPMC5363298 | biostudies-literature
| S-EPMC7335734 | biostudies-literature
| S-EPMC5598083 | biostudies-literature
| S-EPMC4628786 | biostudies-literature